133626-74-1 Usage
Chemical class
Benzodiazepines
Molecular structure
Complex, with ethyl, fluoro, and methyl groups
Pharmacological properties
Sedative, hypnotic, anxiolytic, and muscle relaxant
Potential applications
Pharmacological and medicinal
Effects on the central nervous system
May have effects, but further research is needed
Potential use
Treatment of neurological disorders
Research status
Further research and studies are necessary to understand its pharmacological and therapeutic properties
Molecular weight
Approximately 313.36 g/mol
Appearance
Likely a solid, due to its molecular structure
Solubility
Solubility in water and organic solvents is not specified, but may vary depending on the specific functional groups present
Stability
Stability under different conditions is not specified, but may be influenced by the presence of the fluoro group
Reactivity
Reactivity with other chemicals is not specified, but may be influenced by the presence of the various functional groups in the molecule
Synthesis
The synthesis method for this compound is not provided, but it likely involves the formation of the benzodiazepine ring and subsequent functionalization with the ethyl, fluoro, and methyl groups.
Check Digit Verification of cas no
The CAS Registry Mumber 133626-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,6,2 and 6 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 133626-74:
(8*1)+(7*3)+(6*3)+(5*6)+(4*2)+(3*6)+(2*7)+(1*4)=121
121 % 10 = 1
So 133626-74-1 is a valid CAS Registry Number.
133626-74-1Relevant articles and documents
Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones
Hargrave, Karl D.,Proudfoot, John R.,Grozinger, Karl G.,Cullen, Ernest,Kapadia, Suresh R.,et al.
, p. 2231 - 2241 (2007/10/02)
Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.
